Serum paraoxonase activity in patients with low glomerular filtration rates

Renal Failure

Volumn 32, Issue 5, 2010, Pages 562-565

  Ciftci, Halil ^a   Savas, Murat ^a   Yeni, Ercan ^a   Verit, Ayhan ^a   Çelik, Hakim ^a   Oncel, Halil ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Lower glomerular filtration rate; Oxidative stress; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTETATE TECHNETIUM TC 99M; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY SCINTISCANNING; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; SPECTROPHOTOMETRY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LIPID PEROXIDATION; LIPID PEROXIDES; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL INSUFFICIENCY; YOUNG ADULT;

EID: 77952988392     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003728747     Document Type: Article

References (34)

1. Mcclellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: Important differences between practice and published guidelines. Am J Kidney Dis. 1997;29:368-375.
2. Kausz AT, Khan SS, Abichandani R, et al. Management of patients with chronic renal insufficiency in the northeastern United States. J Am Soc Nephrol. 2001;12:1501-1507.
3. Coresh J, Astor BC, Green T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12.
4. Panzetta O, Cominacini L, Garbin U, et al. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: Effects of fish oil and vitamin E administration. Clin Nephrol. 1995;44:303-309.
5. Cristol JP, Dantoine T, Morena M, et al. Protective effects of HDL against oxidative stress is impaired in hemodialysis patients. Nephrol Dial Transplant. 1997; 12: A156.
6. Witztum IL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793-795.
7. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286:152-154.
8. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275:17527-17535.
9. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
10. Watson AD, Navab M, Hama SY, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774-782.
11. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med. 2004;37:1304-1316.
12. Mackness M, Mackness B. Paraoxonase 1 and atherosclerosis: Is the gene or the protein more important? Free Radic Biol Med. 2004;37:1317-1323.
13. Jarvik GP, Rozek LS, Brophy VH, et al. Furlong CE Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1 (55) genotype. Arterioscler Thromb Vasc Biol. 2000;20:2441-2447.
14. Mackness B, Durrington P, Mc Elduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775-2779.
15. Sarandol A, Sarandol E, Eker SS, et al. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1103-1108.
16. Gomez-Farices MA, McClellan W, Soucie JM, Mitch WE. A prospective comparison of methods for determining if cardiovascular disease is a predictor of mortality in dialysis patients. Am J Kidney Dis. 1994;23:382-388.
17. Owen WF, Madore F, Brenner BM. An observational study of cardiovascular characteristics of long-term end-stage renal disease survivors. Am J Kidney Dis. 1996;28:931-936.
18. Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res. 1998;39:1529-1542.
19. Isik A, Koca SS, Ustundag B, Celik H, Yildirim A. Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol. 2007;26:342-348.
20. Gorog P, Kotak DC, Kovacs IB. Simple and specific test for measuring lipid peroxides in plasma. J Clin Pathol. 1991;44:765-767.
21. National Kidney Foundation. Clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:1-266.
22. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009-1016.
23. Vanholder R, Argiles A, Baurmeister U, et al. Uremic toxicity: Present state of the art. Int J Artif Organs. 2001;24:695-725.
24. Dubourg L, Michoudet C, Cochat P, Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol. 2001;12:1615-1623.
25. Mihoudet C, Baverel G. Metabolism of acetaldehyde in human and baboon renal cortex. FEBS Lett. 1987;216:113-117.
26. Stuveling EM, Hillege HL, Bakker SJ, et al. C-reactive protein is associated with renal function abnormalities in a nondiabetic population. Kidney Int. 2003;63:654-661.
27. Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212-1218.
28. Panichi V, Migliori M, De Pietro S, et al. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron. 2002;91:594-600.
29. Descamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis: Relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995;154:882-892.
30. Dantoine TF, Debord J, Charmes JP, et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol. 1998;9:2082-2088.
31. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase is decreased in uremic patients. Clin Chim Acta. 1996;247:71-80.
32. Bolton CH, Downs LG, Victory J G G, et al. Endothelial dysfunction in chronic renal failure: Roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001;16:1189-1197.
33. Mezzano D, Pais EO, Aranda E, et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int. 2001;60:1844-1850.
34. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998;161:2524-2532.